Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1

Vascular Pharmacology

Volumn 44, Issue 5, 2006, Pages 309-315

  Chen, Lu Lu ^a   Zhang, Jiao Yue ^a   Wang, Bao Ping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Diabetic nephropathies; Extracellular matrix; Plasminogen activator inhibitor 1; Procetofen; Transforming growth factor beta

Indexed keywords

ALBUMIN; FENOFIBRATE; LAMININ; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; EMOTION; EXTRACELLULAR MATRIX; GLUCOSE BLOOD LEVEL; KIDNEY CORTEX; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RAT STRAIN; RECEPTOR UPREGULATION; RENAL PROTECTION; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; ANTILIPEMIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOWN-REGULATION; EXTRACELLULAR MATRIX; FENOFIBRATE; GLUCOSE; HYPOLIPIDEMIC AGENTS; KIDNEY CORTEX; LAMININ; LIPID METABOLISM; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCETOFEN; RATS; RATS, WISTAR; RNA, MESSENGER; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33646156170     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.01.004     Document Type: Article

References (30)

1. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int. J. Clin. Pract. 59 (2005) 102-106
2. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., Steiner G., and DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45 (2005) 485-493
3. Arts J., Kockx M., Princen H.M., and Kooistra T. Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 26-32
4. Banfi C., Auwerx J., Poma F., Tremoli E., and Mussoni L. Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thromb. Haemost. 90 (2003) 611-619
5. Baricos W.H., Reed J.C., and Cortez S.L. Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Exp. Biol. Med. 228 (2003) 1018-1022
6. Brown N.J., Nakamura S., Ma L., Nakamura I., Donnert E., Freeman M., Vaughan D.E., and Fogo A.B. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 58 (2000) 1219-1227
7. Critchley J.A., Zhao H.L., Tomlinson B., Leung W., Thomas G.N., Chan J.C., and Cockram C.S. Management of nephropathy in patients with type 2 diabetes. Chin. Med. J. 115 (2002) 129-135
8. Eddy A.A. Plasminogen activator inhibitor-1 and the kidney. Am. J. Physiol. Renal Physiol. 283 (2002) F209-F220
9. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83 (1998) 683-690
10. Festa A., D'Agostino Jr. R., Tracy R.P., Haffner S.M., and Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51 (2002) 1131-1137
11. Flanders K.C., and Burmester J.K. Medical applications of transforming growth factor-beta. Clin. Med. Res. 1 (2003) 13-20
12. Fogo A.B. Renal fibrosis: not just PAI-1 in the sky. J. Clin. Invest. 112 (2003) 326-328
13. Hill C., Flyvbjerg A., Gronbaek H., Petrik J., Hill D.J., Thomas C.R., Sheppard M.C., and Logan A. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141 (2000) 1196-1208
14. Hirano T., Kashiwazaki K., Moritomo Y., Nagano S., and Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res. Clin. Pract. 36 (1997) 11-18
15. Kockx M., Princen H.M., and Kooistra T. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes-role of the peroxisome proliferator-activated receptor-alpha. Thromb. Haemost. 80 (1998) 942-948
16. Liu Y.Y., Mao L., and Mo Q.Z. An experimental model of NIDDM rat. Chinese J. Endocrinol. Metab. 6 (1990) 115-116
17. Lee H.B., and Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology 10 (2005) S11-S13
18. Ma L.J., Mao S.L., Taylor K.L., Kanjanabuch T., Guan Y., Zhang Y., Brown N.J., Swift L.L., McGuinness O.P., Wasserman D.H., Vaughan D.E., and Fogo A.B. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53 (2004) 336-346
19. Nicholas S.B., Aguiniga E., Ren Y., Kim J., Wong J., Govindarajan N., Noda M., Wang W., Kawano Y., Collins A., and Hsueh W.A. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 67 (2005) 1297-1307
20. Nilsson L., Takemura T., Eriksson P., and Hamsten A. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1577-1581
21. Nordt T.K., Lutzi S., Ruef J., Peter K., Klar E., Kubler W., Sobel B.E., and Bode C. Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells. Thromb. Haemost. 86 (2001) 1305-1313
22. Okopien B., Huzarska M., Kulach A., Stachura-Kulach A., Madej A., Belowski D., Zielinski M., and Herman Z.S. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia. J. Cardiovasc. Pharmacol. 45 (2005) 160-164
23. Paueksakon P., Revelo M.P., Ma L.J., Marcantoni C., and Fogo A.B. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int. 61 (2002) 2142-2148
24. Rerolle J.P., Hertig A., Nguyen G., Sraer J.D., and Rondeau E.P. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 58 (2000) 1841-1850
25. Rerolle J.P., Vigneau C., Hertig A., Berrou J., and Rondeau E. Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology. Nephrologie 22 (2001) 5-13
26. Tsikouris J.P., Suarez J.A., and Meyerrose G.E. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J. Clin. Pharmacol. 42 (2002) 1187-1199
27. Tsimihodimos V., Miltiadous G., Daskalopoulou S.S., Mikhailidis D.P., and Elisaf M.S. Fenofibrate: metabolic and pleiotropic effects. Curr. Vasc. Pharmacol. 3 (2005) 87-98
28. Ye P., Hu X., Liu Y., and Zhao Y. Activation of peroxisome proliferator-activated receptor alpha in human endothelial cells increases plasminogen activator inhibitor type-1 expression. Chin. Med. J. 116 (2003) 29-33
29. Ye P., He Y.L., Wang Q., and Liu Y.X. An exploratory study on mechanism of PPARalpha activators-induced plasminogen activator inhibitor-1 expression in HepG-2 cells. Zhonghua Nei Ke Za Zhi 43 (2004) 743-746
30. Zhao S.P., Li J., Xu Z., Wu J., Li Q., and Ye H. Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits. Clin. Chim. Acta 349 (2004) 81-86